Holen Sie sich die Stockscreener-App
73.77
0.20%
0.15
Handel nachbörslich:
73.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$73.62
Offen:
$74.66
24-Stunden-Volumen:
1.72M
Relative Volume:
0.85
Marktkapitalisierung:
$10.26B
Einnahmen:
$105.82M
Nettoeinkommen (Verlust:
$-829.61M
KGV:
-10.78
EPS:
-6.8429
Netto-Cashflow:
$-548.92M
1W Leistung:
+1.44%
1M Leistung:
-3.51%
6M Leistung:
+15.94%
1J Leistung:
+38.35%
1-Tages-Spanne:
$73.50
$75.98
1-Wochen-Bereich:
$72.39
$76.81
52-Wochen-Spanne:
$47.22
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
73.77 | 10.26B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Wells Fargo | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-18 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa
Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com
Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes - investing.com
Cytokinetics (CYTK) Insider Sell: EVP Research & Development Fad - GuruFocus
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment? - Yahoo Finance
Cytokinetics, Inc. (CYTK) Stock Analysis: Biotech Growth With 51% Upside Potential - DirectorsTalk Interviews
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Cytokinetics to Participate in September Investor Conferences - marketscreener.com
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? - Eastern Progress
Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) director sale under 10b5-1 plan - Stock Titan
Cytokinetics (NASDAQ: CYTK) director moves to sell 5,000 vested shares - Stock Titan
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued? - Yahoo Finance
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential - Investing.com
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential By Investing.com - Investing.com Canada
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM - Yahoo Finance
CYTK5615147 Bond Profile — Key Metrics - TradingView
Cytokinetics (CYTK) CEO exercises options, sells 7,500 shares - Stock Titan
What's Going On With Cytokinetics Stock Today?Cytokinetics (NASDAQ:CYTK) - Benzinga
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy - BioPharma Dive
Cytokinetics, Inc. (CYTK) Stock Analysis: A Biotech Powerhouse with 52.45% Upside Potential - DirectorsTalk Interviews
Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCMHas The Bull Case Changed? - webull.com
Cytokinetics Announces Additional ACACIA-HCM and MAPLE-HCM Results Showing Aficamten Benefits Across Hypertrophic Cardiomyopathy Spectrum - Quiver Quantitative
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion - insights.citeline.com
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Why Cytokinetics (CYTK) Stock Is Down Today - Quiver Quantitative
Cytokinetics details trial win for what could be its next approval - STAT
Cytokinetics Announces Positive Phase 3 ACACIA-HCM Results for Aficamten in Non-Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
Cytokinetics' aficamten showed gains in patient scores and exercise in Phase 3 trial - Stock Titan
Cytokinetics (CYTK) Institutional Ownership 2026 $CYTK - MarketBeat
News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 - Endpoints News
Cytokinetics, Incorporated (CYTK) Stock Analysis: Evaluating a Potential 43% Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 - Yahoo Finance
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease - Endpoints News
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Eastern Progress
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):